دورية أكاديمية
أعرض في EDS

Dissection of an impact of VDR and RXRA on the genomic activity of 1,25(OH) 2 D 3 in A431 squamous cell carcinoma.

التفاصيل البيبلوغرافية
العنوان: Dissection of an impact of VDR and RXRA on the genomic activity of 1,25(OH) 2 D 3 in A431 squamous cell carcinoma.
المؤلفون: Olszewska AM; Department of Histology, Medical University of Gdansk, 1a Debinki, 80-211Gdansk, Poland., Nowak JI; Department of Histology, Medical University of Gdansk, 1a Debinki, 80-211Gdansk, Poland., Myszczynski K; Centre of Biostatistics and Bioinformatics Analysis Medical University of Gdansk, 1aDebinki, 80-211 Gdansk, Poland., Słominski A; Department of Dermatology, University of Alabama at Birmingham, AL 35292, USA; Birmingham Veteran Administration Medical Center, Birmingham, AL 35292, USA., Żmijewski MA; Department of Histology, Medical University of Gdansk, 1a Debinki, 80-211Gdansk, Poland. Electronic address: mzmijewski@gumed.edu.pl.
المصدر: Molecular and cellular endocrinology [Mol Cell Endocrinol] 2024 Mar 01; Vol. 582, pp. 112124. Date of Electronic Publication: 2023 Dec 19.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: North Holland Publishing Country of Publication: Ireland NLM ID: 7500844 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8057 (Electronic) Linking ISSN: 03037207 NLM ISO Abbreviation: Mol Cell Endocrinol Subsets: MEDLINE
أسماء مطبوعة: Publication: Limerick : North Holland Publishing
Original Publication: Amsterdam, North-Holland.
مواضيع طبية MeSH: Calcitriol*/pharmacology , Calcitriol*/metabolism , Carcinoma, Squamous Cell*/drug therapy , Carcinoma, Squamous Cell*/genetics, Humans ; Receptors, Calcitriol/genetics ; Receptors, Calcitriol/metabolism ; Vitamin D/pharmacology ; Genomics ; Vitamin D3 24-Hydroxylase
مستخلص: Background: Human skin is the natural source, place of metabolism, and target for vitamin D 3 . The classical active form of vitamin D 3 , 1,25(OH) 2 D 3 , expresses pluripotent properties and is intensively studied in cancer prevention and therapy. To define the specific role of vitamin D 3 receptor (VDR) and its co-receptor retinoid X receptor alpha (RXRA) in genomic regulation, VDR or RXRA genes were silenced in the squamous cell carcinoma cell line A431 and treated with 1,25(OH) 2 D 3 at long incubation time points 24 h/72 h. Extending the incubation time of A431 WT (wild-type) cells with 1,25(OH) 2 D 3 resulted in a two-fold increase in DEGs (differentially expressed genes) and a change in the amount of downregulated from 37% to 53%. VDR knockout led to a complete loss of 1,25(OH) 2 D 3 -induced genome-wide gene regulation at 24 h time point, but after 72 h, 20 DEGs were found, of which 75% were downregulated, and most of them belonged to the gene ontology group "immune response". This may indicate the existence of an alternative, secondary response to 1,25(OH) 2 D 3 . In contrast, treatment of A431 ΔRXRA cells with 1,25(OH) 2 D 3 for 24 h only partially affected DEGs, suggesting RXRA-independent regulation. Interestingly, overexpression of classic 1,25(OH) 2 D 3 targets, like CYP24A1 (family 24 of subfamily A of cytochrome P450 member 1) or CAMP (cathelicidin antimicrobial peptide) was found to be RXRA-independent. Also, immunofluorescence staining of A431 WT cells revealed partial VDR/RXRA colocalization after 24 h and 72 h 1,25(OH) 2 D 3 treatment. Comparison of transcriptome changes induced by 1,25(OH) 2 D 3 in normal keratinocytes vs. cancer cells showed high cell type specific expression pattern with only a few genes commonly regulated by 1,25(OH) 2 D 3 . Activation of the genomic pathway at least partially reversed the expression of cancer-related genes, forming a basis for anti-cancer activates of 1,25(OH) 2 D 3 . In summary, VDR or RXRA independent genomic activities of 1,25(OH) 2 D 3 suggest the involvement of alternative factors, opening new challenges in this field.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
References: Front Oncol. 2021 Dec 24;11:763895. (PMID: 35004285)
Int J Mol Sci. 2023 Apr 28;24(9):. (PMID: 37175742)
Front Oncol. 2021 Oct 06;11:743667. (PMID: 34692525)
Semin Cancer Biol. 2022 Feb;79:217-230. (PMID: 32485310)
Int J Mol Sci. 2022 Aug 02;23(15):. (PMID: 35955731)
Nat Struct Mol Biol. 2011 May;18(5):556-63. (PMID: 21478866)
Cell Mol Life Sci. 2009 Jan;66(1):9-26. (PMID: 18726069)
Molecules. 2015 Jul 07;20(7):12389-99. (PMID: 26198224)
Oncol Lett. 2020 Apr;19(4):3339-3348. (PMID: 32218869)
Nat Rev Cancer. 2014 May;14(5):342-57. (PMID: 24705652)
J Steroid Biochem Mol Biol. 2013 Jan;133:12-24. (PMID: 22939885)
Genomics. 2003 Jan;81(1):26-33. (PMID: 12573258)
Front Oncol. 2022 Jun 07;12:918340. (PMID: 35747793)
Pharmaceutics. 2021 Jan 29;13(2):. (PMID: 33572963)
Nutrients. 2021 Nov 16;13(11):. (PMID: 34836354)
Best Pract Res Clin Endocrinol Metab. 2011 Aug;25(4):543-59. (PMID: 21872797)
Front Immunol. 2023 Mar 09;14:1131870. (PMID: 36969231)
Eur J Med Chem. 2020 Dec 1;207:112738. (PMID: 32829183)
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):281-5. (PMID: 15225786)
Transl Oncol. 2019 Jan;12(1):15-23. (PMID: 30245304)
Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677)
Int J Biol Macromol. 2022 Jun 1;209(Pt A):1111-1123. (PMID: 35421413)
Steroids. 2023 Nov;199:109288. (PMID: 37549780)
Anticancer Res. 2020 May;40(5):2467-2474. (PMID: 32366390)
BMC Cancer. 2018 May 30;18(1):609. (PMID: 29848298)
Cancers (Basel). 2021 Jun 22;13(13):. (PMID: 34206371)
Exp Dermatol. 2020 Sep;29(9):876-884. (PMID: 32654294)
Mol Pharmacol. 2019 May;95(5):490-506. (PMID: 30782852)
Biochem Cell Biol. 2022 Oct 01;100(5):387-402. (PMID: 35724427)
J Biol Chem. 2010 Oct 8;285(41):31859-66. (PMID: 20682787)
JBMR Plus. 2021 Sep 29;5(12):e10555. (PMID: 34950826)
Int J Mol Sci. 2021 Nov 25;22(23):. (PMID: 34884550)
Nutrients. 2022 Nov 11;14(22):. (PMID: 36432468)
Front Physiol. 2016 Jul 12;7:296. (PMID: 27462278)
Trends Endocrinol Metab. 2010 Nov;21(11):676-83. (PMID: 20674387)
Oncology. 2006;71(1-2):111-23. (PMID: 17377416)
Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Lancet. 1985 Feb 9;1(8424):307-9. (PMID: 2857364)
Acta Biochim Pol. 2014;61(4):679-86. (PMID: 25566549)
Am J Physiol Endocrinol Metab. 2021 Aug 1;321(2):E246-E251. (PMID: 34181461)
J Steroid Biochem Mol Biol. 2016 Nov;164:379-385. (PMID: 26282157)
Cell Death Dis. 2022 Jul 21;13(7):635. (PMID: 35864103)
J Invest Dermatol. 2011 Nov;131(11):2289-97. (PMID: 21814234)
Acta Biochim Pol. 2016;63(1):17-29. (PMID: 26824295)
Lab Invest. 2017 Jun;97(6):706-724. (PMID: 28218743)
Cell Death Dis. 2019 Dec 9;10(12):936. (PMID: 31819048)
J Steroid Biochem Mol Biol. 2017 Oct;173:42-56. (PMID: 27693422)
J Biol Chem. 2009 Jun 19;284(25):16723-16735. (PMID: 19401466)
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560. (PMID: 31114875)
EMBO J. 2002 May 1;21(9):2242-52. (PMID: 11980721)
Nutrients. 2022 Dec 01;14(23):. (PMID: 36501134)
FASEB J. 2022 Aug;36(8):e22451. (PMID: 35838947)
Adv Exp Med Biol. 2020;1268:257-283. (PMID: 32918223)
Nat Commun. 2021 Apr 9;12(1):2130. (PMID: 33837217)
Facial Plast Surg Clin North Am. 2012 Nov;20(4):419-22. (PMID: 23084294)
Science. 2021 Sep 17;373(6561):eabf9232. (PMID: 34529485)
FASEB J. 2014 Jul;28(7):2775-89. (PMID: 24668754)
Carcinogenesis. 2002 Dec;23(12):2103-9. (PMID: 12507934)
Endocrinology. 1981 Mar;108(3):1083-6. (PMID: 6257495)
Adv Exp Med Biol. 2014;810:303-28. (PMID: 25207373)
Int J Oncol. 2016 Dec;49(6):2255-2264. (PMID: 27779648)
Endocrinology. 2000 Mar;141(3):1281-4. (PMID: 10698207)
J Cutan Pathol. 2004 Mar;31(3):224-31. (PMID: 14984574)
Nutrients. 2016 Mar 02;8(3):135. (PMID: 26950144)
Oncol Rep. 2022 Jan;47(1):. (PMID: 34738627)
J Biol Chem. 2002 Jul 12;277(28):25125-32. (PMID: 11991950)
Sci Rep. 2021 Apr 13;11(1):8002. (PMID: 33850196)
J Endocr Soc. 2020 Feb 08;4(2):bvz038. (PMID: 32051922)
Calcif Tissue Int. 2013 Feb;92(2):77-98. (PMID: 22782502)
Mol Pharmacol. 2012 Jul;82(1):37-46. (PMID: 22474172)
Biomolecules. 2020 Mar 24;10(3):. (PMID: 32213983)
Indian J Pathol Microbiol. 2020 Jul-Sep;63(3):382-387. (PMID: 32769326)
J Exp Clin Cancer Res. 2020 Jul 29;39(1):144. (PMID: 32727517)
Physiol Rev. 2016 Jan;96(1):365-408. (PMID: 26681795)
Nutrients. 2022 Mar 30;14(7):. (PMID: 35406059)
Mol Biol Rep. 2020 Mar;47(3):2181-2187. (PMID: 32072405)
Int J Mol Sci. 2018 Oct 08;19(10):. (PMID: 30297679)
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. (PMID: 30476243)
Cell Biochem Biophys. 2020 Jun;78(2):165-180. (PMID: 32441029)
Cancer Prev Res (Phila). 2020 Aug;13(8):673-686. (PMID: 32467291)
Lancet. 1979 Dec 22-29;2(8156-8157):1335-6. (PMID: 92676)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Expert Rev Clin Pharmacol. 2019 Oct;12(10):947-951. (PMID: 31524530)
Pharmacol Ther. 2018 Jan;181:34-48. (PMID: 28723413)
Sci Rep. 2021 Mar 22;11(1):6518. (PMID: 33753848)
Proc Natl Acad Sci U S A. 2019 May 28;116(22):10911-10916. (PMID: 31097581)
PLoS One. 2013;8(1):e54716. (PMID: 23349955)
Am J Pathol. 2020 Apr;190(4):900-915. (PMID: 32035061)
Physiol Genomics. 2021 Jun 1;53(6):235-248. (PMID: 33900108)
Trends Pharmacol Sci. 2018 Mar;39(3):307-325. (PMID: 29254698)
Recent Results Cancer Res. 2003;164:259-69. (PMID: 12899528)
Cancer Prev Res (Phila). 2011 Sep;4(9):1485-94. (PMID: 21733837)
Biomed Pharmacother. 2019 Jan;109:391-401. (PMID: 30399574)
J Cell Physiol. 1999 Feb;178(2):188-96. (PMID: 10048583)
BMC Cancer. 2021 Dec 13;21(1):1327. (PMID: 34903206)
Hematol Oncol Clin North Am. 2019 Feb;33(1):1-12. (PMID: 30497667)
Adv Exp Med Biol. 2014;810:282-302. (PMID: 25207372)
J Steroid Biochem Mol Biol. 2013 Jul;136:271-9. (PMID: 23059470)
Front Immunol. 2016 Dec 21;7:629. (PMID: 28066438)
Sci Rep. 2019 Mar 7;9(1):3877. (PMID: 30846808)
J Am Acad Dermatol. 2017 May;76(5):958-972.e2. (PMID: 28259441)
Sci Rep. 2016 Aug 03;6:30698. (PMID: 27485575)
Int J Oncol. 2022 Aug;61(2):. (PMID: 35775377)
J Innate Immun. 2012;4(1):31-40. (PMID: 21912088)
J Invest Dermatol. 2017 Dec;137(12):2613-2619. (PMID: 28774592)
J Clin Invest. 2017 Jan 3;127(1):106-116. (PMID: 27869649)
Can J Physiol Pharmacol. 2015 May;93(5):349-54. (PMID: 25559384)
J Cell Biochem. 2003 Feb 1;88(2):296-307. (PMID: 12520530)
Nutrients. 2022 Mar 24;14(7):. (PMID: 35405966)
Front Oncol. 2021 Jan 08;10:570736. (PMID: 33489879)
Mayo Clin Proc. 2016 Mar;91(3):386-96. (PMID: 26944243)
Future Oncol. 2021 Feb;17(5):611-627. (PMID: 33052055)
J Cancer. 2020 Aug 15;11(20):5971-5981. (PMID: 32922538)
معلومات مُعتمدة: I01 BX004293 United States BX BLRD VA; R01 AR071189 United States AR NIAMS NIH HHS; R01 AR073004 United States AR NIAMS NIH HHS; R21 AI149267 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Calcitriol; Keratinocytes; Retinoid X receptor; Squamous cell carcinoma; Vitamin D(3); Vitamin D(3) receptor
المشرفين على المادة: FXC9231JVH (Calcitriol)
66772-14-3 (1,25-dihydroxyvitamin D)
0 (Receptors, Calcitriol)
1406-16-2 (Vitamin D)
EC 1.14.15.16 (Vitamin D3 24-Hydroxylase)
0 (VDR protein, human)
تواريخ الأحداث: Date Created: 20231220 Date Completed: 20240205 Latest Revision: 20240218
رمز التحديث: 20240218
مُعرف محوري في PubMed: PMC10872374
DOI: 10.1016/j.mce.2023.112124
PMID: 38123121
قاعدة البيانات: MEDLINE
الوصف
تدمد:1872-8057
DOI:10.1016/j.mce.2023.112124